Bastian, Mike http://orcid.org/0000-0001-8347-7426
Freemantle, Nick
Rossi, Ana B. http://orcid.org/0000-0001-5345-678X
Shumel, Brad http://orcid.org/0000-0002-9285-8164
Le Bagousse, Gaelle Bego
Wang, Zhixiao
Xu, Yingxin
Guyot, Patricia
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi
Article History
Received: 11 December 2023
Accepted: 22 January 2024
First Online: 16 February 2024
Declarations
:
: Mike Bastian: Sanofi—employee and may hold stock and/or stock options in the company; Nick Freemantle: grants from the National Institute for Health and Care Research, the Medical Research Council, Cure Parkinson's Trust, and the European Union, consultancy fees from ALK, Sanofi Aventis, Gedeon Richter, Abbott, Galderma, AstraZeneca, Ipsen, Vertex, Thea, Novo Nordisk, Aimmune, and Ipsen, and honorarium from Abbott Singapore; Ana B Rossi: Sanofi—employee and may hold stock and/or stock options in the company; Brad Shumel: Regeneron—employee and shareholder; Gaelle Bego Le Bagousse: Sanofi—employee and may hold stock and/or stock options in the company; Zhixiao Wang: Regeneron—employee and shareholder; Yingxin Xu: Regeneron—employee and shareholder; Patricia Guyot: Sanofi—employee and may hold stock and/or stock options in the company.
: This letter is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.